密集游说后，特朗普签了！大麻和泰诺同类

Core Viewpoint - The signing of the executive order by President Trump on December 18 aims to reclassify cannabis from a Schedule I controlled substance to a Schedule III controlled substance, which will facilitate medical research and exploration of cannabis's benefits and potential harms [1][3]. Group 1: Regulatory Changes - The reclassification will lower the barriers for medical research on cannabis, allowing it to be recognized for certain medical uses [3]. - Schedule III substances are defined as having a moderate to low risk of physical and psychological dependence, which includes some common medications like Tylenol with codeine [3]. - The executive order mandates the U.S. Attorney General to expedite the process of relaxing federal restrictions on cannabis, although no specific timeline is provided [3]. Group 2: Political and Industry Support - The cannabis industry has engaged in extensive lobbying efforts to encourage the Trump administration to ease cannabis regulations, receiving significant support from various political factions [4][5]. - The "American Rights and Reform Political Action Committee," backed by the cannabis industry, has made substantial donations to Trump's campaign, including $1 million to the "Make America Great Again" super PAC [5]. - Key executives from major cannabis companies have met with Trump to discuss the potential for job creation and the need for regulatory changes [6]. Group 3: Public Perception and Criticism - Critics warn that lowering the classification of cannabis may send a misleading message about its dangers, potentially normalizing its use among the public, especially youth [9]. - The cannabis industry is viewed as a multi-billion dollar sector, with increasing accessibility and potential for growth, despite ongoing federal restrictions [10].